|
|
|
|
||
Re: VRTX and D-Ivacaftor/TRIKAFTA FDA ApprovalDoes the FDA approval (6 months early) for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Treat the Underlying Cause of Cystic Fibrosis in People Ages 12 and Older Who Have at Least One F508del Mutation include CNCE's VX-561? If it does, it could trigger the $90 Million contingent payable to CNCE on approval in US and EU. Red |
return to message board, top of board |
Msg # | Subject | Author | Recs | Date Posted |
1483 | Re: VRTX and D-Ivacaftor/TRIKAFTA FDA Approval/Not VX-561 | redhotace | 2 | 10/25/2019 10:49:48 PM |